Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
RADA Electronic Industries (RADA) 6.9M Stock Offering Prices at $1.23/Share
-
RADA Announces Pricing Of Public Offering Of Its Ordinary Shares
-
EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants
-
EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants
-
Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors
-
Chardan Capital Sees Axovant's (AXON) RVT-101 Only Costing $5M Upfront; 'Sell' Rating Affirmed
-
Esperion Therapeutics (ESPR) PT Cut to $40 at Chardan Capital Markets
-
VistaGen Therapeutics (VSTA) Highlighted at Chardan Capital After Allergan Acquires Comp Naurex
-
IDI, Inc. Announces $10 Million Registered Direct Offering
-
Chardan Capital Trims PT on Axovant (AXON) to $9.50; News is Good, but 24+ Late-Stage Alzheimer's Drugs in Development
-
Chardan Capital Markets Starts Applied Genetic Technologies Corp. (AGTC) at Buy
-
Notable Analyst Rating Changes 7/15: (GES) (CSX) (LNKD) Upgraded; (LLY) (LPLA) (CINF) Downgraded
-
OncoCyte Announces Appointment of Andy Arno to Board of Directors
-
Chardan Capital Markets Starts Energous Corp (WATT) at Buy; Apple, LG, Microsoft or Samsung Seen as Tier 1 Customer
-
MassRoots Closes $1 Million Financing Round
-
PlacementTracker Publishes First Half 2015 PIPE Market League Tables
-
Chardan Capital Says Esperion Therapeutics (ESPR) Concerns 'Unanswered' Despite Lifting of FDA Hold
-
Market Wrap: Horizon Pharma Gets Hostile on Depomed; Tesla Slumps on Downgrade; U.S. Trade Deficit Widens in May
-
Unusual 11 Mid-Day Movers 7/7: (DEPO) (PBMD) (IPDN) Higher; (ETRM) (STV) (BZUN) Lower
-
Chardan Capital Markets Announces Hiring of Andy Arno to The Special Equities Group
-
Chardan Capital Markets Remains Bullish Following Digital Ally (DGLY) Q2 Pre-Release
-
Digital Ally (DGLY) Prelim. Q2 Results Outpace, But Chardan Capital Remains Skeptical on FY15 Op. Income Outlook
-
Pre-Open Stock Movers 07/07: (DEPO) (PBMD) (PNK) Higher; (ETRM) (AMD) (SHLM) Lower (more...)
-
UPDATE: Chardan Upgrades Himax (HIMX) to Buy Ahead of Microsoft's (MSFT) Announcement on Hololens Availability
-
La Jolla Pharma (LJPC) PT Raised to $60 at Chardan Capital Markets
-
Streetinsider.com's Hot Lunchtime Reads 7/2: (VRTX) (TWTR) (AMD) (MDCO) (AMBA)
-
Vislab Adds Computer Vision to Ambarella's (AMBA) Portfolio; Chardan Affirms at 'Neutral'
-
Viggle Announces the Closing of a $4.2 Million Underwritten Sale of Common Stock to a Single Institutional Investor
-
Viggle (VGGL) Prices 2.05M Common Stock Offering $2.05/Share
-
Viggle Announces Pricing of $4.2 Million Underwritten Sale of Common Stock to a Single Institutional Investor
-
Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering
-
Blue Earth (BBLU) Enters 1.67M Common Stock, Warrants Direct Offering
-
Blue Earth Announces $2 Million Registered Direct Offering
-
Immune Pharma (IMNP) Announces Date to Commence Bertilimumab Phase II Bullous Pemphigoid Trial
-
Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid
-
Ritter Pharmaceuticals (RTTR) IPO Opens Flat
-
Ritter Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
-
Chardan Capital Markets Upgrades Avalanche Biotechnologies (AAVL) to Neutral
-
Chardan Capital Starts Signal Genetics (SGNL) at Buy; MyPRS Test Could See Big Demand
-
Ritter Pharmaceuticals (RTTR) Amends IPO Filing; Plans to Offer 4M Shares and Sees Price of $5/Share
-
Notable Analyst Rating Changes 6/18: (JNPR) (HOG) (AMC) Upgraded; (RATE) (LUV) (NMBL) Downgraded
-
Pre-Open Stock Movers 06/18: (LMNS) (DGLY) (BMRN) Higher; (HERO) (RATE) (ORCL) Lower (more...)
-
Chardan Capital Starts VistaGen Therapeutics (VSTA) at Buy; Positive on AV-101 as Antidepressant Sans Ketamine Side Effects
-
Chardan Capital Markets Starts Axovant Sciences (AXON) at Sell; RVT-101 Remains Overrated
-
Chardan Capital Markets Starts Digital Ally (DGLY) at Buy; FirstVu Should be Key Source of Growth
-
Chardan Capital Trims PT on Profire Energy (PFIE) to $1.80; FY16 Outlook 'Sharply' Lower than Expected
-
Chardan Capital Markets Downgrades Avalanche Biotechnologies (AAVL) to Sell
-
Esperion Therapeutics (ESPR) Price Target Lowered to $50 at Chardan
-
Chardan Capital Markets Upgrades MaxLinear (MXL) to Buy
-
Chardan Capital Boosts PT on Ambarella (AMBA) to $90; Stock Continues Defying Conventional Wisdom

